The adipose tissue which was earlier viewed as a simple energy storage tissue is now taken as a major endocrine system. It secretes hormones -adiponectin, resistin, leptin and ghrelin. The concentration of all these hormones depends upon the BMI. In humans, plasma adiponectin concentrations decrease with obesity and are positively associated with whole body insulin sensitivity. Resistin is known to antagonize insulin action. In addition, fat releases non -esterified fatty acid in the circulation which are proinflammatory in nature, leading to the development of endothelial dysfunction and subsequently cardiovascular disease. Hence, overweight / obesity is a serious issue especially in diabetics, cardiovascular disease etc. The obesity management in these cases calls in for individualized exercise plan with target heart rate range to be given after the study of their cardio -pulmonary status. The resistance exercises give completion to the exercise plan. The behavioural modification and dietery supplement which enhance beta -cell oxidation and avoidance of certain food items example: refined flour and processed food item are prescribed.
Indian Journal of Clinical Biochemistry, December 2007, Vol. 22 (Supl.) 
19S2.2
Modulation of Lipoprotein(a) Levels in Ischemic Stroke: Effect of Aspirin Therapy JK Gambhir, Harsimrut Kaur, GS Ranga, OP Kalra Department of Biochemistry and Medicine, University College of Medical Sciences and GTB Hospital, Shahdara, Delhi.
Hyperlipidemia and increased lipoprotein(a)[Lp(a)] levels are risk factors for coronary artery disease (CAD) and ischemic stroke. Most of the drugs used to treat hyperlipidemia are not effective in decreasing Lp(a) levels. Therefore, we have evaluated the effect of aspirin therapy on Lp(a) levels in patients with ischemic stroke. Serum levels of Lp(a) and lipid profile parameters were measured in 25 patients with first ever diagnosed ischemic stroke at admission and four weeks after treatment with aspirin (150mg daily). Lp(a) levels were significantly higher in patients as compared to healthy controls (27.4±22.3 vs 14.7±11.8 mg/dL, p<0.005). After four weeks of aspirin therapy, Lp(a) levels declined significantly from baseline levels to 14.7±10.5 mg/dL (46.2 % decrease, p<0.001). Patients with baseline Lp(a) levels >25mg/dL showed greater decline compared to those with levels <25 mg/dL (55.6% vs 26.6% p<0.008). Results of our study suggest that raised Lp(a) is a strong risk factor for ischemic stroke and aspirin therapy leads to significant decrease in Lp(a) levels.
Curriculum Vitae: Hypertension is a major public health problem worldwide with a prevalence of 26.4%. ApoA1 is the major apolipoprotein of HDL which has been associated with protection against atherosclerosis. Apo A1 serves as a co-factor for efficient reverse cholesterol transport. This study is aimed at evaluating whether different alleles of Apo A1 are associated with hypertension .The GG , GA and AA alleles at -75 region of ApoA1 gene were studied. The study group consisted of 100 patients including 50 patients of primary hypertension in the age group 35-60 yrs with controls matched for age and sex. Routine biochemical parameters were done on Synchron CX4. The allelelic profile of each case was evaluated by DNA extraction , PCR amplification using appropriate primers , digestion by restriction enzyme Msp 1 and vizualization of the agarose electrophoresis bands. The results were statistically analyzed using students t test .The allelic frequency was calculated. The allelic frequency of G was 0.63 in hypertensives and O.82 in controls . The allelic frequency of A allele was 0.37 in hypertensives and 0.18 in controls . The presence of GA allele was 69 % in hypertensives and only 36 % in contols. This difference was statistically significant. In the routine parameters we found lipid profile deranged in hypertensives. Hypertension is a heterogenous disorder with gene-environment interactions playing a major role . Though environmental risk factors are well studied the genetic predisposition to hypertension is not well documented. In our study on G-75A allele we found ,the majority of hypertensive patients had GA heterozygous genotype . Further studies on a larger scale are required to ascertain whether gene polymorphism of the Apo A1 gene at the -75 site and heterozygosity predisposes to primary hypertension .
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Ritu Singh, MBBS, MD and FIMSA She did her MD in 1991. She has a WHO fellowship in Lab Genetics. She is currently Associate Professor. Dept. of Biochemsitry, Lady Hardinge Medical College and SSK Hospital. Her areas of interest are:-Down's syndrome -pre-natal diagnosis and biochemical parameters/atherosclerotic risk in Down's children; with special reference to apoA, gene polymorphism (G-75A and C83T alleles). She has published four international and ten national research papers. She has wirtten three chapters in e-books on Molecular physiology by NISCAIR, CSIR E-mail: mail2rs@indiatimes. It has already been established that non HDL cholesterol is better predictor of cardio vascular disease(CVD) than HDL cholesterol. The diabetic type II patients of the age group 45-65 years are in the high risk population.Smoking, stress and alcohol trigger the risk.A study was made in Bengali population from West Bengal and Bangladesh of 45-65 years age group as factors like food habit, life style, physical appearance are common. Sixty people volunteered as normal healthy control. Apparently, the control group are nonsmoker, non alcohol user with normal ECG reports. 950 diabetic type II with familial hyperlipidemia were chosen.Amongst them 250 patients were occasional alcohol user and chronic smoker. 350 are female patients and having no history of smoking or alcohol use. Rest 350 patients are of the age group 50-65, getting treatment for diabetes and hyperlipidemia of which 50 had suffered once from myocardial infarction(MI). Basal metabolic index, blood glucose, total cholesterol(TC), HDL cholesterol(HDLC), LDL cholesterol (LDLC), VLDL cholesterol(VLDLC), apolipoprotein B(apoB) were estimated. CPK & CPKMB of the MI patients were also measured. Atherogenic index (AI) and small dense LDL values were calculated from TC/HDLC ratio,LDL/LDLapoB ratio. AI and small dense LDL values were found out to be high in diabetic dyslipidaemia patients.There are no significant change in those values in MI patients. Amongst 250 patients used to smoking and occasional alcohol, though apoB values are on the higher side(70 cases) small dense LDL became high only in 30 cases. AI is normal for all the cases. Probably TC,LDLC and apoB are better predictors of CVD.
Curriculum Vitae: Advanced lipoprotein testing includes determination of LDL particle size, LDL particle number, and Apo B. LDL particle size may be determined by gradient gel electrophoresis or density gradient electrophoresis. Both techniques are logistically unsuitable for clinical purposes. Small dense (SD) LDL preponderance can be predicted in presence of low HDL and elevated triglycerides. Its utility as an independent CHD risk predictor is also questionable. Those with SD LDL commonly have diabetes mellitus, abdominal obesity, hypertension, or history of smoking -all of which anyway increase the risk of CHD. There is also no specific therapy for SD LDL and there is lack of RCT data showing that increasing LDL size reduces CHD risk. Risk prediction of cardiovascular disease by a large number of LDL particles (LDL-P) by NMR spectroscopy may be superior to LDL-C. Yet, LDL-P was found to be an independent CHD risk predictor in only 7 out of 14 prospective studies. In recent studies, the incremental value of LDL-P was abolished after adjustment for TG and HDL-C. In one study, CHD risk prediction by TC:HDL-C ratio was close to LDL-P. Apo B may be superior to cholesterol indices to assess the risk of vascular disease and adequacy of lipidlowering drug therapy. Yet AMORIS, the largest study that supported ApoB as the strongest predictor of risk of fatal MI did not adjust for potential confounders. In Atherosclerosis Risk in Communities (ARIC), the risk attributable to ApoB was eliminated in multivariate analysis. In the Health Professional Follow up Study, the relative risk (RR) of CHD was almost identical for apo B and non-HDL-C and non-HDL-C was the best predictor of cardiovascular disease (CVD) in type 2 diabetes mellitus. In Women's Health Initiative, Non-HDL-C and TC:HDL-C ratio were found to be best predictors of CVD in women > 45 years. In another case-control study, non-HDL-C was found to be the best predictor of MI in the young amongst all studied lipid risk factors including apo B. Thus, while apoB can be estimated in non-fasting sample, its superiority over non-HDL-C has not been unequivocally demonstrated. Use of apo B in clinical practice is limited by lack of reference values and non-availability of automated immunoturbidimetery. Thus, in practice, lipid profile and its simple derivatives e.g. non-HDL-C levels and TC/HDL-C ratio seem to provide sufficient information for CHD risk assessment.
